




RealRate

# PHARMACEUTICAL 2018

## Vanda Pharmaceuticals Inc. Rank 119 of 342





RealRate

# PHARMACEUTICAL 2018

## Vanda Pharmaceuticals Inc. Rank 119 of 342



The relative strengths and weaknesses of Vanda Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vanda Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 89% points. The greatest weakness of Vanda Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 151%, being 105% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	169,857
Cost of Goods Sold	0
Intangible Assets	26,069
Liabilities, Current	70,363
Liabilities, Non-Current	3,675
Other Assets	4,193
Other Compr. Net Income	-92
Other Expenses	19,734
Other Liabilities	0
Other Net Income	0
Other Revenues	166,555
Property and Equipment	5,306
Research and Development	38,547
Selling, General and Administrative Expense	123,841

Output Variable	Value in 1000 USD
Assets	205,425
Liabilities	74,038
Expenses	182,122
Revenues	166,555
Stockholders Equity	131,387
Net Income	-15,567
Comprehensive Net Income	-15,613
Economic Capital Ratio	151%